Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer

作者：Longyang Liu, Zhaoyang Zeng, Juanjuan Yi, Liu Zuo, Jin Lv, Jianhuan Yuan, Zhongqiu Lin, Rongcheng Luo, Xin Feng · 发表于：Cancer Biomarkers · 年份：2019 · DOI：10.3233/cbm-181849 · 被引用次数：18 · 研究领域：Ferroptosis and cancer prognosis、Wnt/β-catenin signaling in development and cancer、Ovarian cancer diagnosis and treatment

OBJECTIVES: To investigate TCF4 expression in epithelial ovarian cancer, and to explore its correlation with clinicopathological parameters and clinical prognosis of epithelial ovarian cancer. METHODS: From 2009 to 2017, 188 cases of paraffin-embedded epithelial ovarian cancer tissues and 41 paratumor ovarian tissues which had been confirmed at the memorial hospital of Sun Yat-sen University were collected in this study, and the expression of TCF4 was performed by immunohistochemistry using a polyclonal antibody specific for TCF4. RESULTS: The expression of TCF4 protein was associated with disease progression free survival and overall survival in epithelial ovarian cancer patients; and TCF4 overexpression was associated with age, FIGO stage, lymph node metastasis, intraperitoneal metastasis, intestinal metastasis, vital status, intraperitoneal recurrence, and serum CA153. Moreover, in a multivariate Cox regression analysis TCF4 overexpression was an indeed independent prognostic factor in epithelial ovarian cancer. CONCLUSIONS: TCF4 may play an oncogenic role in epithelial ovarian cancer, and TCF4 is a useful independent prognostic biomarker of epithelial ovarian cancer, and it may provide a candidate target therapy treatment in future.